Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q3 FY2023 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, Feb 20, 2023
Slide 1: Exchange filing cover letter
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com February 20, 2023 To, Listing Department, Listing Department, The BSE Lim
Slide 2: NGL Fine-Chem Limited Investor Presentation Q3FY23
NGL Fine-Chem Limited INVESTOR PRESENTATION Q3FY23
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof ) delivered or supplied should not be
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 08 Q3FY23 Over view, Highlights Key Strengths and Strategy Pg. No. 14 Historical Financial Performance
Slide 5: Q3FY23 Highlights
01 Q3FY23 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, Despite these challenges, we remained steadfast I am pleased to provide an update on our in our commitment to preserving customer performance during the third quarter of fiscal relationships, maintaining market share, and year 23. Despite the challenges posed
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q3FY22 Q2FY23 Q3FY23 PARTICULARS Q3FY22 Q2FY23 Q3FY23 ANIMAL API 87% 83% 81% TOP 3 PRODUCTS 38% 27% 39% HUMAN API 7% 8% 5% TOP 5 PRODUCTS 53% 41% 51% INTERMEDIATES 4% 6% 8% TOP 10 PRODUCTS 77% 72% 76% FORMULATIONS 2% 4% 6% G
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q3FY22 Q2FY23 Q3FY23 Q-o-Q Y-o-Y 9MFY22 9MFY23 Y-o-Y REVENUE FROM OPERATIONS 81.14 67.72 71.93 6.22% -11.35% 235.46 200.26 -14.95% OTHER INCOME 3.84 0.47 0.69 46.81% -82.03% 12.54 6.48 -48.33% TOTAL REVENUE 84.98 68.19 72.62 6.50% -14.54%
Slide 9: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 A D VA N TA G E O U S LY P L A C E D I N A G R O W I N G OPPORTUNITY 15 S T R AT E G Y
Slide 10: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 24 APIs (22 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs, 2 Huma
Slide 11: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 34% CAGR CONCENTRATION (OF SALES FY22) backward integrated facilities leading to cost competitiveness FY22 258 CUSTOMER PRODUCT F
Slide 12: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 13: Advantageously Placed in a Growing Opportunity
Advantageously Placed in a Growing Opportunity MARKET SIZE 2020 MARKET SIZE 2027 SEGMENT TRENDS GROWTH DRIVERS • Pharma segment to • Rising prevalence of grow at higher rate – zoonotic diseases, 5.4% CAGR $139 Billion $192 Billion animal population & pet ownership • Production animal ANIMAL HEALTH (
Slide 14: Strategy for Next Leg of Growth
Strategy for next leg of growth BROWNFIELD EXPANSION OUTSOURCE PRODUCTION DE-BOTTLENECKING • Completed ₹ 26 Cr expansion in • Target to outsource production • Continuous debottlenecking & ONGOING INITIATIVES subsidiary Macrotech to 15% by FY24 process improvements TO INCREASE • Additional capacities
Slide 15: Historical Financial Performance
03 Historical Financial Performance 17 ROBUST FINANCIAL PERFORMANCE 18 IMPROVING EFFICIENCIES
Slide 16: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT 27% 28% 35% (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) CAGR CAGR CAGR FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 FY19 153 FY19 32 FY19 20 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROSS
Slide 17: Improving Efficiencies
Improving Efficiencies ROCE Debt/Equity Fixed asset turnover (VALUES IN %) (VALUES IN X) (VALUES IN X) 60% 4 53% 0. 30 3.4 3.4 0.25 3. 5 50% 0.23 0. 25 3 40% 2.5 34% 2.3 0. 20 2. 5 30% 27% 2 0.13 0. 15 1. 5 20% 0. 10 12% 0.07 1 10% 0. 05 0. 5 0% 0 0. 00 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 F
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M